6. •Emergency physician at Henry
ford Hospital, Detroit
•Study was conducted in 2001
•Aim was to evaluate efficacy of
EGDT before ICU admission
7.
8.
9.
10. Supportive Evidence
Quality / Grade A B C D E F
Outstanding • Rivers,NEJM,
2001
Good Nguyen,CCM,2007;
Ferrer, JAMA 2008
Adequate Micek, CCM, 2006; Kortgen,
El Sohl, J Am Ger CCM,
Soc, 2008 2006
19. 2. Obtaining blood cultures before administering
antibiotics:
– Collection strategy:
• Two or more culture from percut and veach vascular
access device
• Wound, urine, sputum, CSF, ascitic fluid, pleural fluid
– Indications:
• Fever, chills, hypothermia, leukocytosis, renal failure,
hemodynamic compromise, other unexplained organ
dysfunction
20. 3. Administer broad spectrum antibiotics:
– Timing of antibiotic:
• Once sepsis is identified, antimicrobial agent should be
administered as soon as possible.
• Adequate antibiotic therapy is required.
– Choice of antibiotic:
• Use broad spectrum antibiotics until specific pathogen is
identified
• Use combination of antibiotics initially
– Re-evaluation after 24-48 hours:
• Once organism is identified, restrict antibiotic to specific
pathogen narrow the spectrum
21.
22.
23. 4. Administer 30 ml/kg crystalloid for
hypotension and lactate > 4 mmol/L:
24. • Initial fluid resuscitation
– 30 ml/kg, as early as possible after diagnosis
– Requirement is not easy calculate, so repeated
boluses should be given
– Target : CVP > 8 mmHg
Lactate clearance
ScvO2 > 70%
25. t
• SSC recommends MAP of
at least 65 mmHg.
•Whether this is effective
or not in unknown
•Aim of this trial was to
study significant difference
between high target blood
pressure and low target
blood pressure group
26.
27. Lower v/s higher hemoglobin threshold
for blood transfusion in septic shock
• Multicenter, RCT
• To establish harms and benefits of blood
transfusion in patients with high and low
threshold level
• High threshold <9 g/dl
• Low threshold < 7 g/dl
• Primary outcome – 90 days mortality
Published in NEJM.org on October 1, 2014
28. •Total 1545 blood transfusion
were given to low threshold
group v/s 3040 to high
threshold group (p<0.001)
•176 patients (36.1%) in low
threshold group didn’t undergo
transfusion as compared to only
6 patients (1.2%) in high
threshold.
30. • Aim : whether River’s findings were
generalized and whether all aspects of
protocol were necessary.
• Patients were divided in three groups:
– Protocol based EGDT
– Protocol based standard therapy
– Usual care
31.
32. •No benefit of CV line and central
monitoring in all patients
•Two protocol based
management lead to initial
transient improvement in blood
pressure, but a higher
requirement of intensive care
and renal replacement therapy.
•No significant difference in
mortality
33.
34.
35. • Question: Does EGDT compared with standard
care decrease mortality at 90 days?
• Design:
– Multi centered, RCT
– 51 hospitals from 2008-2014
– Around 1600 patients
36.
37.
38. • Strength of the study:
– Clinical relevance
– Large multi center study
– Use of original EGDT algorithm
– No confounding effect of antibiotic administration
– Statistical analysis
• Bottom line:
– Contradictory to EGDT, continuous central venous
oximetry, liberal blood transfusion policy and
dobutamine
– Early recognition, source control, early antimicrobial
therapy, fluid resuscitation and escalation remain
fundamental goals
39. • ARISE and PROCESS have not demonstrated
any adverse outcome in groups using CVP and
ScvO2 monitoring. So no harm in continuing
SSC bundle
• SSC will review their bundle and treatment
plan and update accordingly
• For now, no change in 3 hour bundle pattern
40. • Objective:
– Determine the association between compliance
with SSC bundle and mortality
• Design:
– Based on 2004 SSC guidelines
– Data collection from 2005 to 2012
– 218 hospitals from US, South America and Europe
41. • Results:
– Hospital mortality rate dropped 0.7% per site for
every 3 months of participation (p<0.001)
– Hospital and ICU LOS decreased 4% (p-0.012) for
every 10% increase in site compliance with
resuscitation bundle.
Compliance High Low P value
Resuscitation bundle 29.0% 38.6% <0.001
Management bundle 33.4% 32.3% 0.039
42. • Purpose:
– To describe and compare the design of three multi
centered independent trials on EGDT for severe
sepsis and septic shock
• Conclusion:
– Harmonization is feasible
– Facilitate pooling of data on completion of trials
After arterial and central venous catheterization
standard-therapy group - treated at the clinicians’ discretion according to a protocol for hemodynamic support, admitted for inpatient care as soon as possible, cultures were obtained before antibiotics, Antibiotic were given at the discretion of the treating clinicians
early goal-directed therapy - central venous catheter capable of measuring central venous oxygen saturation, at least six hours and were transferred to the first available inpatient beds
Protocol - 500-ml bolus of crystalloid every 30 mins, central venous pressure of 8 to 12 mm Hg;
Grade A Randomized clinical trials or meta-analyses (multiple clinical trials) or randomized clinical trials (smaller
trials),directly addressing the review issue
Grade B Randomized clinical trials or meta-analyses (multiple clinical trials) or randomized clinical trials (smaller
trials), indirectly addressing the review issue
Grade C Prospective, controlled, non-randomized, cohort studies
Grade D Retrospective, non-randomized, cohort or case-control studies
EGDT – no arterial line placement, otherwise rest was same as River’s
Protocol bases standard care – no art line, their own 6 hour bundle, CV line only if peripheral line is inadequate, fluid and vasoactive drugs to reach goals of SBP and shock index, hourly assessment of fluid status, packed cell transfusion only if HB<7.5
Usual care – bed side provider directed care
Inclusion criteria – SIRS with refractory hypotension, administration of antibiotics before randomization
Exclusion – CVC insertion or blood products, active bleeding and hemodynamic instability
EGDT – art line and CV line with scvO2 monitoring
Control – Art line or CVC if clinically appopriate, no scvO2